PG-530742

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C24H27N3O7S
Molecular Weight	501.552
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC(CC#CCN3CCOCC3)C(O)=O

InChI

InChIKey=JAYVKNDQKXUNOJ-UHFFFAOYSA-N

InChI=1S/C24H27N3O7S/c1-33-20-9-5-18(6-10-20)23(28)25-19-7-11-21(12-8-19)35(31,32)26-22(24(29)30)4-2-3-13-27-14-16-34-17-15-27/h5-12,22,26H,4,13-17H2,1H3,(H,25,28)(H,29,30)

HIDE SMILES / InChI

Molecular Formula	C24H27N3O7S
Molecular Weight	501.552
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16814643 | https://www.ncbi.nlm.nih.gov/pubmed/17958901 | https://www.ncbi.nlm.nih.gov/pubmed/18096086 | https://adisinsight.springer.com/drugs/800020080

PG-116800 is a member of the hydroxyproline-based hydroxamic acid class of matrix metalloproteinase (MMP) inhibitors. PG-116800 did not modify matrix structure in osteoarthritic patients. Also, it had unexpected side effects on muscle and skeleton; it limited joint mobility, and caused arthralgia, hand oedema, palmar fibrosis, Dupuytren’s contracture and persistent tendon thickness or nodules. PG-116800 failed to reduce left ventricular remodeling or improve clinical outcomes after myocardial infarction.

Originator

Approval Year

PubMed

Title	Date	PubMed
The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors.	2006 Feb 15	16413004
Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.	2006 Jul 4	16814643
Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.	2006 Jun	16428338
The quest for the Holy Grail: a disease-modifying osteoarthritis drug.	2007	18096086
Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study.	2007	17958901

Sample Use Guides

In Vivo Use Guide

25 mg, 50 mg, 100 mg, or 200 mg taken twice daily for 12 months

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 02:31:10 GMT 2023` Edited by `admin` on `Sat Dec 16 02:31:10 GMT 2023`
Record UNII	F94T42GL80
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PG-530742

Common Name

English

PG-116800

Code

English

PGE7113313

Code

English

PGE-7113313

Code

English

4-HEXYNOIC ACID, 2-(((4-((4-METHOXYBENZOYL)AMINO)PHENYL)SULFONYL)AMINO)-6-(4-MORPHOLINYL)-

Common Name

English

Code System Code Type Description

MESH

C512048